EMA validates marketing authorization for DATROWAY® in triple negative breast cancer
The European Medicines Agency (EMA) has officially validated the marketing authorization application for DATROWAY® (datopotamab deruxtecan), a novel antibody-drug conjugate (ADC), for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not eligible for PD-1/PD-L1 inhibitors.


-1-640x358.jpg&w=3840&q=75)



-640x359.jpg&w=3840&q=75)



